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Mammalian target of rapamycin (mTOR) is a serine–threonine kinase that acts
downstream of the phosphatidylinositol 3-kinase signaling pathway and regu-
lates a wide range of cellular functions including transcription, translation, prolif-
eration, apoptosis, and autophagy. Whereas genetic alterations that result in
mTOR activation are frequently present in human cancers, whether the mTOR
gene itself becomes an oncogene through somatic mutation has remained
unclear. We have now identified a somatic non-synonymous mutation of mTOR
that results in a leucine-to-valine substitution at amino acid position 2209 in a
specimen of large cell neuroendocrine carcinoma. The mTOR(L2209V) mutant
manifested marked transforming potential in a focus formation assay with mouse
3T3 fibroblasts, and it induced the phosphorylation of p70 S6 kinase, S6 riboso-
mal protein, and eukaryotic translation initiation factor 4E–binding protein 1 in
these cells. Examination of additional tumor specimens as well as public and in-
house databases of cancer genome mutations identified another 28 independent
non-synonymous mutations of mTOR in various cancer types, with 12 of these
mutations also showing transforming ability. Most of these oncogenic mutations
cluster at the interface between the kinase domain and the FAT (FRAP, ATM,
TRRAP) domain in the 3-D structure of mTOR. Transforming mTOR mutants were
also found to promote 3T3 cell survival, and their oncogenic activity was sensi-
tive to rapamycin. Our data thus show that mTOR acquires transforming activity
through genetic changes in cancer, and they suggest that such tumors may be
candidates for molecularly targeted therapy with mTOR inhibitors.
M ammalian target of rapamycin (mTOR) is a serine–thre-onine kinase and a component, together with the rapamy-
cin-sensitive regulatory associated protein of mTOR or the
rapamycin-insensitive companion of mTOR, of mTOR complex
1 (mTORC1) or mTORC2, respectively.(1) From its amino-ter-
minus, mTOR contains HEAT (huntingtin, elongation factor 3,
protein phosphatase 2A, TORI) repeat, FAT (FRAP, ATM,
TRRAP), FRB (FK506-rapamycin binding), amino-terminal
lobe of the kinase, LBE (LST8 binding element), carboxyl-ter-
minal lobe of the kinase, and FATC (FRAPP, ATM, TOR at C-
terminus) domains. Whereas the molecular mechanism by which
the kinase activity of mTOR is regulated remains unclear,
mTOR acts downstream of the phosphatidylinositol 3-kinase
(PI3K) signaling pathway. One cascade leading to mTOR activa-
tion, for instance, involves activation of the serine–threonine
kinase AKT in a manner dependent on PI3K, phosphorylation of
tuberous sclerosis complex (TSC) 1 ⁄2 by AKT, consequent
loading of Rheb with GTP, and activation of mTORC1. Ligand
binding to many receptor-type tyrosine kinases thus results in
the activation of mTOR through PI3K.
Activated mTOR regulates a plethora of cellular activities
including gene transcription, translation, cell growth and pro-
liferation, apoptosis, and autophagy.(1–3) For example, mTOR
phosphorylates and thereby activates p70 S6 kinase
(p70S6K), which is a positive regulator of cell size and
mRNA translation.(4) Also, eukaryotic translation initiation
factor 4E binding protein 1 (4EBP1) becomes directly phos-
phorylated by mTOR, and dissociated from eukaryotic trans-
lation initiation factors, allowing ribosome entry into 50-cap
site of mRNAs.
Consistent with the importance of mTOR in the regulation
of cell growth and proliferation as well as of protein synthesis,
multiple genetic alterations that lead to mTOR activation have
been identified in human cancers.(5, 6) Activating somatic
mutations in the catalytic subunit of PI3K, for instance, are
among the most frequent oncogenic changes in tumors. Loss-
of-function mutations of phosphatase and tensin homolog,
which counteracts PI3K activity, are also frequently detected.
Activating mutations of AKT1 and AKT3 have been associ-
ated with breast cancer and melanoma, respectively, and
genetic loss of TSC1 has been observed. Such genetic changes
commonly lead to the activation of mTOR, and blockade of
such signaling with mTOR-specific inhibitors has proven to be
of clinical benefit.
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Whether mTOR itself becomes a bona fide oncoprotein as a
result of somatic genomic alterations in cancer has remained
elusive. Forced introduction of amino acid substitutions into
mTOR has been shown to result in activation of its kinase
function or to confer transforming activity,(7–9) whereas dele-
tion of the inhibitory domain also leads to mTOR activa-
tion,(10) revealing an oncogenic potential for mTOR. Sato
et al.(11) searched non-synonymous mTOR mutations in the
COSMIC cancer mutation database (http://cancer.sanger.ac.uk/-
cancergenome/projects/cosmic/), and found seven independent
mutations. Then they revealed that E2419K, S2215Y, and
R2505P substitutions elevate enzymatic activity of mTOR, but
failed to demonstrate transforming ability. Thus, it is not set-
tled yet if mTOR mutations found in human cancer confer
direct transforming potential.
We have now identified somatic single nucleotide variations
in a specimen of large cell neuroendocrine carcinoma
(LCNEC), one of which results in a Leu2209-to-Val substitution
in mTOR. The mTOR(L2209V) mutant was found not only to
mediate marked phosphorylation of p70S6K but also to possess
transforming ability when expressed in mouse 3T3 fibroblasts.
Moreover, approximately half of the amino acid substitutions
in mTOR listed in the cancer database similarly confer onco-
genic activity.
Materials and Methods
Clinical specimens and cell lines. Surgically resected tumor
and paired normal specimens from LCNEC patients were ana-
lyzed with written informed consent. This study was approved
by the institutional ethics committees of The University of
Tokyo (Tokyo, Japan) and Chiba University (Chiba, Japan).
Mouse 3T3 and HEK293T cells were obtained from ATCC
(Manassas, VA, USA), and were maintained in DMEM-F12
supplemented with 10% FBS and 2 mM L-glutamine (all from
Invitrogen, Carlsbad, CA, USA).
Exome analysis with next generation sequencer. Exon frag-
ments were isolated from genomic DNA of an LCNEC tumor
(#G4T) and its matched normal control specimen with the use
of a SureSelect Human All Exon kit (Agilent Technologies,
Santa Clara, CA, USA). Nucleotide sequencing of these frag-
ments was carried out with the HiSeq2500 platform (Illumina,
San Diego, CA, USA) with the paired-end option. We selected
only sequence reads with a Q value of ≥20 at each base, and
further extracted unique reads that were subsequently mapped
to the reference human genome sequence (hg19) with the use
of the Bowtie 2 algorithm (http://bowtie-bio.sourceforge.net/
bowtie2/index.shtml). Mismatches were discarded if: (i) a
given read contained ≥3 independent mismatches; (ii) they
were already present in the “1000 genomes” database (http://
www.1000genomes.org) or included in the normal human gen-
ome variations of our in-house database; or (iii) they were sup-
ported by only one strand of the genome. Somatic mutations
were called with the MuTect algorithm (http://www.broadinsti-
tute.org/cancer/cga/mutect) and annotated with SnpEff (http://
snpeff.sourceforge.net). A genomic region corresponding to
Leu2209 of mTOR was amplified by PCR with the primers 50-
CCTCCTACCTTGGCATTACA-30 and 50-CGCTCCCACTG
TTCCTTACA-30 (forward and reverse, respectively), and the
PCR products were sequenced by the dye-termination method.
Functional analyses. Wild-type human mTOR cDNA was
obtained by PCR, and its mutant forms were generated with
the use of a QuickChange site-directed mutagenesis kit (Agi-
lent Technologies). All cDNA sequences were verified by the
dye-termination method and were then ligated into the pMXS
retroviral vector (Cell Biolabs, San Diego, CA, USA). The
recombinant plasmids were introduced together with packaging
plasmids (Takara Bio, Shiga, Japan) into HEK293T cells in
order to obtain recombinant infectious virus particles.
For a focus formation assay, 3T3 cells were infected with
the ecotropic recombinant retroviruses with the use of 4 lg
⁄mL polybrene (Sigma-Aldrich, St. Louis, MO, USA) for 24 h,
and further cultured in DMEM-F12 supplemented with 5% calf
serum (Invitrogen) for up to 2 weeks. Cell transformation was
assessed either by phase-contrast microscopy or by staining
with the Giemsa solution.
For immunoblot analyses, 3T3 cells were lysed by NP-40
lysis buffer containing 1% NP-40, 50 mM Tris-HCl, 150 mM
Fig. 1. Transforming activity of the mammalian
target of rapamycin (mTOR)(L2209V) mutant. (a)
Domain organization of human mTOR showing the
positions of non-synonymous mutations (trans-
forming ones shown in red) detected in human
cancers. (b) Sequencing electrophoretograms for PCR
products corresponding to the region of the mTOR
gene containing codon 2209 that were obtained
from large cell neuroendocrine carcinoma tumor
#G4T or its paired normal sample. (c) Mouse 3T3
fibroblasts infected with recombinant retroviruses
encoding v-Ras, mTOR, or mTOR(L2209V), or with
the corresponding empty virus (Mock), were cultured
in the presence of 5% calf serum for 12 days and
then examined by phase-contrast microscopy. Scale
bar = 100 lm. FAT, FRAP, ATM, TRRAP; FATC, FRAPP,
ATM, TOR at C-terminus; FRB, FK506-rapamycin
binding; HEAT, huntingtin, elongation factor 3,
protein phosphatase 2A, TORI; LBE, LST8 binding
element.
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NaCl, 1 mM sodium fluoride, 1 mM sodium vanadate, and
1 mM PMSF (all from Sigma-Aldrich). Cell lysates were sepa-
rated by 7.5% SDS-PAGE, and subjected to immunoblot anal-
ysis. Antibodies used were #2972 for mTOR, #9202 for
p70S6K, #9234 for phosphorylated p70S6K, #2217 for S6RP,
#4857 for phosphorylated S6RP, #9644 for 4EBP1, #2855 for
phosphorylated 4EBP1, #4691 for AKT, #4060 for phosphory-
lated AKT, and #4970 for ACTB (all from Cell Signaling
Technology, Danvers, MA, USA). Rapamycin was obtained
from Merck Millipore (Billerica, MA, USA).
For the cell number analysis, 1 9 104 of 3T3 cells at 48 h
after the infection with recombinant retrovirus were seeded
into each well of 96-well plates. The next day, the medium
was changed to DMEM-F12 with various concentrations of
calf serum, and further cultured for 36 h. Cell number was
assessed with a luminometer by using CellTiter-Glo Lumines-
cent Cell Viability assay (Promega, Madison, WI, USA). At
the same time, cells were subjected to measuring the caspase
3 ⁄ caspase 7 activity by using the Caspase-Glo 3 ⁄7 assay sys-
tem (Promega).
Results
mTOR(L2209V) is a transforming mutant. Full-exome sequenc-
ing for an LCNEC specimen (#G4T) and its paired normal
cells (PBMCs) obtained from a 70-year-old man identified a
total of 167 somatic missense single nucleotide variations
(Table S1) including one for a Leu2209-to-Val substitution in
mTOR (Fig. 1a, Table S2). Sanger sequencing of the #G4T
genome confirmed a heterozygous C-to-G mutation in codon
2209 (Fig. 1b). Given that it has been unclear whether mTOR
can function as an oncoprotein as a result of its own genomic
changes in cancer, we examined the transforming ability of
mTOR(L2209V) in a focus formation assay. Expression of
mTOR(L2209V) induced marked transformation of mouse 3T3
cells, whereas that of the wild-type protein did not (Fig. 1c).
As a positive control, the v-Ras oncoprotein also readily trans-
formed 3T3 cells, although the morphology of the transformed
cells was distinct from that of those expressing mTOR
(L2209V). These results indicated that mTOR can become a
bona fide oncoprotein as a result of a somatic mutation found
in human cancer.
Various amino acid substitutions confer transforming ability on
mTOR. Our exome sequencing of other LCNEC samples did not
reveal additional tumors positive for mTOR(L2209V), but iden-
tified two independent somatic non-synonymous mutations
(p.D258H and p.R1235P) of mTOR (data not shown). Searches
of the COSMIC database as well as our in-house sequencing
data for mTOR mutations identified an additional 26 amino acid
Fig. 2. Transforming amino acid changes in
mammalian target of rapamycin (mTOR). Mouse
3T3 cells were infected with recombinant
retroviruses encoding each mTOR mutant, wild-type
mTOR, or v-Ras or with the corresponding empty
virus (Mock). The cells were cultured in the
presence of 5% calf serum for 10 days and then
stained with Giemsa solution.
Fig. 3. Intracellular signaling evoked by transforming mammalian
target of rapamycin (mTOR) mutants and rapamycin sensitivity of
transforming activity. (a) Mouse 3T3 cells were lysed 3 days after
infection with recombinant retroviruses encoding wild-type or trans-
forming mutants of mTOR. The cell lysates were subjected to immuno-
blot analysis with antibodies to total or phosphorylated (p-) forms of
the indicated proteins. ACTB served as a loading control. (b) Mouse
3T3 cells infected with recombinant retroviruses encoding v-Ras, wild-
type mTOR, mTOR(T1977I), mTOR(L2209V), or mTOR(S2215Y) were cul-
tured in the presence of 5% calf serum (CS) and with or without
100 pM rapamycin for 12 days and then examined by phase-contrast
microscopy. Scale bar = 1 mm.
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substitutions in various cancer specimens and the OCUM-2M
gastric cancer cell line (Fig. 1a, Table S2).(12) Of note, recurrent
sites for missense mutations, including Thr1977 and Ser2215, were
apparent.
We constructed recombinant retroviruses encoding each of
the identified mTOR mutants and used them for focus forma-
tion assays with mouse 3T3 cells. Unexpectedly, approxi-
mately half of these mutants manifested transforming activity
(Fig. 2, Fig. S1). Whereas the morphology of the transformed
cells appeared similar (Fig. S1), the extent of the malignant
change (the number of piled-up foci) varied substantially
among the mutants. For example, mTOR(T1977K), mTOR
(T1977R), mTOR(S2215F), and mTOR(S2215Y) showed
marked transforming potential, whereas that of mTOR
(L2220F) and mTOR(D2512H) appeared less pronounced.
Intracellular signaling evoked by oncogenic mTOR. The vari-
ous transformed 3T3 cell lines were then examined for the
activation status of signaling molecules downstream to
mTOR (Fig. 3a). First, immunoblot analysis with antibodies
to mTOR revealed that each mTOR mutant was expressed
at a similar level, although some mutants (such as R2505P)
were more abundant than the others. Phosphorylation of
p70S6K at Thr389 was induced by most of the transforming
mutants, although such induction was minimal or non-exis-
tent for mTOR(E1799K), mTOR(L2220F), and mTOR
(D2512H). Of note, the ability of the mutants to phosphory-
late p70S6K appeared to correlate approximately with their
transforming potential (Fig. 2, Fig. S1). Activated p70S6K
phosphorylates S6 ribosomal protein (S6RP), which in turn
promotes mRNA translation. Marked phosphorylation of
S6RP at Ser235/236 was evident in the 3T3 cell lines that
manifested increased activation of p70S6K (Fig. 3a). Simi-
larly, 4EBP1, another substrate of mTOR, was phosphory-
lated at Thr37/46 in 3T3 cells expressing the transforming
Fig. 4. Promotion of cell survival by oncogenic mammalian target of rapamycin (mTOR) mutants. (a) Mouse 3T3 cells infected with recombinant
retroviruses encoding v-Ras, wild-type mTOR, mTOR(T1977I), mTOR(L2209V) or mTOR(S2215Y), or empty virus (Mock) were cultured in the pres-
ence of 5%, 0.3%, or 0% calf serum for 36 h and then examined by phase-contrast microscopy. Scale bar = 100 lm. (b) The same sets of 3T3 cells
after incubation for 36 h with various concentrations of calf serum were subjected to cell number assessment with a luciferase-based assay. The
luciferase activity of each fraction is normalized by that of the mock-infected 3T3 cells cultured without calf serum, and is shown as mean  SD
of three independent experiments. (c) Caspase 3/caspase 7 activity was measured in 3T3 by a luciferase-based assay after culturing without calf
serum for 36 h. Luciferase activity in each fraction is normalized by the corresponding cell number, and further normalized by that of the mock-
infected 3T3 cells. Data are means  SD in triplicate experiments.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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mTOR mutants, although to a lesser extent compared with
S6RP phosphorylation.
Whereas mTORC2 directly phosphorylates AKT, activated
p70S6K phosphorylates and negatively regulates insulin recep-
tor substrate 1.(13) As insulin receptor substrate 1 is an impor-
tant upstream activator of PI3K–AKT, phosphorylation of
p70S6K, thus, evokes a physiological negative feedback loop
toward AKT.(5) Phosphorylation of AKT at Ser473 was slightly
attenuated in 3T3 cells expressing active mTOR mutants com-
pared with that in those expressing the wild-type protein
(Fig. 3a), consistent with a previous observation.(8)
Transforming activity of mTOR mutants is rapamycin sensi-
tive. Mammalian target of rapamycin acts as a catalytic sub-
unit of both mTORC1 and mTORC2. Given that the macrolide
rapamycin inhibits the activity of mTORC1, but not that of
mTORC2 in vitro,(14) we tested whether the transforming
activity of mTOR mutants is sensitive to rapamycin. Mouse
3T3 cells expressing T1977I, L2209V, or S2215Y mutants of
mTOR (which are among those with the greatest transforming
activity) were subjected to a focus formation assay in the
absence or presence of 100 pM rapamycin. Whereas all three
mutants (but not the wild-type protein) generated malignant
foci in the absence of rapamycin, this effect was not apparent
in the presence of the drug (Fig. 3b, Fig. S2). The transform-
ing ability of these mTOR mutants is thus sensitive to rapamy-
cin.
Cell survival signaling by oncogenic mTOR mutants. Active
mTORC1 and mTORC2 induce cell survival signals.(15) We
therefore examined whether transforming mutation of mTOR
promotes cell survival. The 3T3 cells infected with recombi-
nant retroviruses encoding wild-type mTOR, mTOR(T1971I),
mTOR(L2209V), or mTOR(S2215Y) were cultured in the
presence of 5%, 0.3%, or 0% calf serum for 36 h (Fig. 4a,b).
Whereas cells infected with the empty virus proliferated in the
presence of 5% serum, they ceased to do so in the presence of
0.3% or 0% serum. Similarly, 3T3 cells infected with the virus
for wild-type mTOR decreased in number as the serum con-
centration decreased. In contrast, cells expressing the trans-
forming mutants of mTOR continued to proliferate even in the
absence of serum. Cells expressing v-Ras also generated
abnormal foci under all three serum conditions. The serum
deprivation-induced activation of caspase 3 ⁄ caspase 7 was par-
tially suppressed when 3T3 cells expressed v-Ras or active
mTOR mutants (Fig. 4c). Therefore, oncogenic mutations of
mTOR confer anti-apoptotic functions as well.
Discussion
We have here shown that mTOR becomes activated and
acquires direct transforming ability as a result of amino acid
substitutions found in human cancer cells. The mTOR gene
thus becomes an oncogene through genetic alteration. How-
ever, we failed to observe tumor formation in a nude mouse
tumorigenicity assay for 3T3 cells expressing mTOR mutants,
whereas those expressing v-Ras did generate s.c. tumors in the
same observation period (data not shown). The transforming
ability of mTOR mutants may, therefore, be less potent than
that of v-Ras.
As expected, oncogenic mTOR mutants activated down-
stream signaling molecules such as p70S6K, S6RP, and
4EBP1 in 3T3 cells. Furthermore, cells expressing such mTOR
mutants were more resistant to nutrient deprivation than were
those expressing the wild-type protein. Our observations that
the proliferation of cells expressing these mTOR mutants was
sensitive to rapamycin and that AKT was not activated in
these cells suggest that such mutants exert their transforming
action through mTORC1. Artificially generated active mutants
of mTOR similarly confer resistance to nutrient deprivation
and induce phosphorylation of S6RP.(7) However, given that
long-time treatment with rapamycin can also affect mTORC2
activity in some cell types,(16) whether mTORC1 is the only
complex that mediates the starvation resistance of cells
expressing transforming mTOR mutants requires further exam-
ination.
Yang et al.(17) reported that artificially generated transform-
ing mutations are widely distributed in the 3-D structure of
mTOR. They are enriched in several “limiting active-site
access” regions including the catalytic cleft and the amino-ter-
minal portion of FAT. In contrast, most of the naturally occur-
ring transforming mutations (E1799K, L2209V, S2215F ⁄Y,
L2220F, V2406A, R2505P, and D2512H) cluster in an unex-
pectedly narrow region of the structure (Fig. 5). They are thus
localized at an interacting surface between the carboxyl-termi-
nal lobe of the kinase domain and the FAT domain, the latter
of which forms a “C”-shaped clamp for the former. Whether
these mutations loosen the binding between the FAT and
kinase domains and thereby render the kinase domain more
open and active remains to be determined. Our findings sug-
gest that the FAT domain plays a key role in the regulation of
mTOR activity.
The FRB domain is thought to function as a gatekeeper for
the mTOR catalytic site.(17) It prevents the entry of non-sub-
strate peptides, but allows that of genuine ones. Importantly,
two activating mutation sites (Thr1977 and Val2006) are posi-
tioned close to each other in the vicinity of the FRB domain
(Fig. S3). Substitution of these residues thus likely affects the
structure or position of the FRB domain.
In general, transforming mutations of protein tyrosine
kinases cluster in the activation loop of the catalytic domain.
In contrast, groups of activating mutation sites, such as those
in the vicinity of the FRB and FAT domains, are located out-
side of the catalytic domain in mTOR. This finding may be
due to the fact that mTOR is intrinsically active and negatively
regulated by the FRB and FAT domains.(17)
We have thus shown that mTOR becomes an oncokinase in
human cancer as a result of amino acid substitutions, and that
Fig. 5. Cluster of transforming amino acid substitutions at the inter-
action surface between the carboxyl-terminal lobe of the kinase
domain and the FAT (FRAP, ATM, TRRAP) domain of mammalian tar-
get of rapamycin (mTOR). The structure of human mTOR (ID “4JSP” in
the Protein Data Bank, http://www.pdb.org) is presented schemati-
cally, with a helices and b sheets shown in cyan and magenta, respec-
tively. Oncogenic mutation sites (E1799, L2209, S2215, L2220, V2406,
R2505, and D2512) and ATP are shown as spherical models. The posi-
tions of the kinase and FAT domains are also indicated.
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the transforming activity of this oncokinase is sensitive to
rapamycin. Inhibitors of mTOR are currently in use clinically
for the treatment of renal cell carcinoma, but whether such
tumors harbor oncogenic mTOR mutations is not examined in
the clinics. Our results have shown that transforming mTOR
mutants are distributed across various cancer types (albeit at a
low frequency), suggesting that clinical trials with mTOR inhi-
bitors are warranted for individuals with such tumors positive
for oncogenic mTOR mutations.
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Supporting Information
Additional supporting information may be found in the online version of this article:
Fig. S1. Focus formation assay for mammalian target of rapamycin (mTOR) mutants. Mouse 3T3 cells were infected with recombinant retro-
viruses encoding each mTOR mutant shown in Figure 1(a), wild-type mTOR, or v-Ras or with the corresponding empty virus (Mock). The cells
were cultured for 10 days in the presence of 5% calf serum and then examined by phase-contrast microscopy. Scale bar = 100 lm.
Fig. S2. Transforming activity of mammalian target of rapamycin (mTOR) mutants is rapamycin sensitive. Mouse 3T3 cells infected with recom-
binant retroviruses encoding v-Ras, wild-type mTOR, mTOR(T1977I), mTOR(L2209V), or mTOR(S2215Y) were cultured in the presence of 5%
calf serum and with or without 100 pM rapamycin for 12 days and then stained with Giemsa solution.
Fig. S3. Positions of Thr1977 and Val2006 in human mammalian target of rapamycin (mTOR). The 3-D structure of mTOR is shown schematically
as in Figure 5. Thr1977, Val2006, and ATP are shown as spherical models.
Table S1. Somatic missense single nucleotide variations detected in patient #G4T with large cell neuroendocrine carcinoma.
Table S2. Non-synonymous mutations of mammalian target of rapamycin (mTOR) in human cancer.
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